EGFR and familial pancreatic carcinoma: With a goal to investigate the chronotherapeutic potential of a targeted agent based on our transcriptome data, we evaluated temporal cell viability after treatment with erlotinib, an EGFR inhibitor that is used to inhibit cell replication by targeting EGFR in pancreatic cancer (51).